Key Highlights
- Revenue of USD 3.82 million compared with a USD 1.28 million estimate.
- Loss per share of USD 0.06, where a USD 0.08 loss was expected.
- Cash, deposits and marketable securities were about USD 117.5 million.
- MAIA-Ovarian enrollment is complete, and data are expected by the end of Q1 2027.
Compugen (NASDAQ:CGEN) booked Revenue of USD 3.82 million in the third quarter of 2026, where the market had expected USD 1.28 million. The loss was USD 0.06 per share, against an estimated USD 0.08 loss. The chief financial officer put revenue at about USD 3.8 million, against about USD 1.9 million in the same quarter of 2025.
In both periods, revenue reflected recognition of parts of the upfront payment and the IND milestone payment under the license agreement with Gilead (NASDAQ:GILD). The net loss for the quarter was about USD 5.8 million, or USD 0.06 per basic and diluted share, against about USD 7 million, or USD 0.07 per share, in the third quarter of 2025. Research and Development expenses were about USD 5.8 million in each of the third quarters of 2026 and 2025, and general and administrative expenses were about USD 2.3 million.
Cash and Runway
At September 30, 2026, the company held about USD 117.5 million in cash, cash equivalents, short-term bank deposits and investments in marketable securities. Management said that, with no further cash inflows assumed, this funds its operating plans into 2029, and it described quarterly expenses as in line with plans.
MAIA-Ovarian Reaches Full Enrollment
President and chief executive officer Eran Ophir, the chief financial officer and the chief medical officer joined the call. Management described the Balance Sheet as solid at quarter end and said enrollment is complete in MAIA-Ovarian, a global randomized trial of COM701, a potential first-in-class anti-PVRIG antibody, as maintenance monotherapy in second- and third-line relapsed platinum-sensitive ovarian cancer. The company expects to report data by the end of the first quarter of 2027, a date management repeated it looks forward to meeting.
Partnered Programs and Milestones
The company says its partnered programs carry the potential for more than USD 1 billion in future milestone payments and royalties. In the quarter, AstraZeneca (NASDAQ:AZN) presented first overall survival data from the Phase II ARTEMIDE-01 study in first-line PD-L1 positive non-small cell lung cancer at the World Conference on Lung Cancer. Compugen is eligible for up to USD 195 million in regulatory and commercial milestones and up to mid-single-digit royalties on worldwide sales of rilvegostomig.
Under the Gilead agreement, Compugen has received gross payments of USD 90 million and can earn up to USD 758 million in further milestone payments, plus tiered royalties ranging from single digits to low double digits.



![Arch Biopartners Inc. Turns Heads as Phase II kidney-drug development Sparks New Trading Interest on the TSXV Composite — Small Cap Growth Stock [TSXV:ARCH]](/featured_image/gallery/medium/shutterstock_2606085317_11_18_2026_16_10_43_645635.jpg)
![Vimy Pharmaceuticals Corp. Momentum Jumps as its new-listing debut Puts the TSXV Composite in Focus — Small Cap-Growth Stock [TSXV:VIMY]](/featured_image/gallery/medium/shutterstock_512538715_11_18_2026_16_11_17_989273.jpg)
![WELLSTAR Technologies Corp. Momentum Jumps as record public-company quarterly growth Puts the TSXV Composite in Focus — Small Cap-Growth Stock [TSXV:WSTR]](/featured_image/gallery/medium/shutterstock_2439951387_11_18_2026_16_11_37_467341.jpg)
Please wait processing your request...